NCT03331588 is a Phase 3 clinical trial of Subxiphoid uniportal VATS in Lung Neoplasms, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT03331588?

NCT03331588 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT03331588?

Interventions in NCT03331588: Subxiphoid uniportal VATS, Intercostal uniportal VATS.

What condition does NCT03331588 study?

NCT03331588 studies Lung Neoplasms, Thoracic Surgery, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Carcinoma, Bronchogenic, Thoracic Neoplasm.

Is NCT03331588 still recruiting?

NCT03331588 is currently completed. Last updated 2 March 2020.

Last reviewed 2020-03-02 · How we verify

NCT03331588

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer

Completed Phase 3 Last updated 2 March 2020

What this trial tests

Phase 3 trial testing Subxiphoid uniportal VATS in Lung Neoplasms in 200 participants. Completed in 28 February 2020.

Timeline

10 November 2017

Primary endpoint
28 February 2020

28 February 2020

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	10 November 2017
Primary completion	28 February 2020
Estimated completion	28 February 2020
Sites	1 location across China

Drugs / interventions tested

Subxiphoid uniportal VATS
Intercostal uniportal VATS

Conditions studied

Lung Neoplasms — all drugs for Lung Neoplasms →
Thoracic Surgery — all drugs for Thoracic Surgery →
Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
Lung Diseases — all drugs for Lung Diseases →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 18 to 80, any sex, with Lung Neoplasms or Thoracic Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

One-thirds of patients underwent video-assisted thorascopic surgery (VATS) still have severe pain.Uniportal lobectomy or segmentectomies emerged as a promising and exciting approach for minimally invasive thoracic surgery. However, nearly all reported uniportal VATS lobectomies have been performed via the intercostal route, and chest wall trauma has still occurred. Here,the investigators undertook novel uniportal VATS technique involving a subxiphoid route for pulmonary lobectomies or segmentectomies.We would like to evaluate the post-operative pain and quality of life between Subxiphoid and Intercostal VATS for Lung Cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Early postoperative pain after subxiphoid uniportal thoracoscopic major lung resection: a prospective, single- blinded, randomized controlled trial.
Chen Z, Jiang L, Zheng H, Zhang W, et al · · 2022 · cited 18× · PMID 35579360 · DOI 10.1093/icvts/ivac133
Randomized controlled trials in lung cancer surgery: How are we doing?
Wong LY, Li Y, Elliott IA, Backhus LM, et al · · 2024 · cited 1× · PMID 38690441 · DOI 10.1016/j.xjon.2024.01.008
Subxifoid versus transthoracic thoracoscopic lobectomy: Results of a retrospective analysis before and after matching analysis.
Andreetti C, Peritore V, Ibrahim M, Gagliardi A, et al · · 2021 · PMID 33689213 · DOI 10.1111/1759-7714.13778

Verify or expand the search:

Other trials of Subxiphoid uniportal VATS

Trials testing the same drug.

NCT03521986 — Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS · Phase 3 · unknown

Other recruiting trials for Lung Neoplasms

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07109154 — DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First- · recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting
NCT07165691 — TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics · NA · recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03331588 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 2 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03331588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing